Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DFP-10917 |
Synonyms | |
Therapy Description |
DFP-10917 is a deoxycytidine analog that inhibits DNA polymerase activity and induces DNA damage, potentially leading to cell cycle arrest and inhibition of tumor growth (PMID: 30668890, PMID: 29344636). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DFP-10917 | DFP 10917|DFP10917|CNDAC|TAS109|TAS-109|TAS 109 | Chemotherapy - Antimetabolite 14 | DFP-10917 is a deoxycytidine analog that inhibits DNA polymerase activity and induces DNA damage, potentially leading to cell cycle arrest and inhibition of tumor growth (PMID: 30668890, PMID: 29344636). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03926624 | Phase III | Decitabine + Venetoclax Azacitidine + Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin Cytarabine + Venetoclax Cytarabine + Filgrastim + Fludarabine Decitabine Azacitidine Cladribine + Cytarabine + Filgrastim + Mitoxantrone DFP-10917 Cladribine + Cytarabine + Filgrastim + Idarubicin Cytarabine Cytarabine + Etoposide + Mitoxantrone | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Unknown status | USA | 0 |